title: Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis.
abstract: OBJECTIVE
  To evaluate pretherapy ribonucleotide reductase (RNR) expression and its effect on radiochemotherapeutic outcome in women with cervical cancer.
  
  
  METHODS
  Pretherapy RNR M1, M2, and M2b immunohistochemistry was done on cervical cancer specimens retrieved from women treated on Radiation Therapy Oncology Group (RTOG) 0116 and 0128 clinical trials. Enrollees of RTOG 0116 (node-positive stages IA-IVA) received weekly cisplatin (40 mg/m(2)) with amifostine (500 mg) and extended-field radiation then brachytherapy (85 Gy). Enrollees of RTOG 0128 (node-positive or bulky ≥5 cm, stages IB-IIA or stages IIB-IVA) received cisplatin (75 mg/m(2)) on days 1, 23, and 43 and 5-FU (1 g/m(2) for 4 days) during pelvic radiation then brachytherapy (85 Gy), plus celecoxib (400 mg twice daily, day 1 through 1 year). Disease-free survival (DFS) was estimated univariately by the Kaplan-Meier method. Cox proportional hazards models evaluated the impact of RNR immunoreactivity on DFS.
  
  
  RESULTS
  Fifty-one tissue samples were analyzed: 13 from RTOG 0116 and 38 from RTOG 0128. M1, M2, and M2b overexpression (3+) frequencies were 2%, 80%, and 47%, respectively. Low-level (0-1+, n = 44/51) expression of the regulatory subunit M1 did not associate with DFS (P = 0.38). High (3+) M2 expression occurred in most (n = 41/51) but without impact alone on DFS (hazard ratio, 0.54; 95% confidence interval, 0.2-1.4; P = 0.20). After adjusting for M2b status, pelvic node-positive women had increased hazard for relapse or death (hazard ratio, 5.5; 95% confidence interval, 2.2-13.8; P = 0.0003).
  
  
  CONCLUSIONS
  These results suggest that RNR subunit expression may discriminate cervical cancer phenotype and radiochemotherapy outcome. Future RNR biomarker studies are warranted.
authors.affiliation: University Hospitals of Cleveland, Cleveland, OH, USA. kunosc@summahealth.org
authors.forename: Charles A
authors.initials: CA
authors.lastname: Kunos
authors.forename: Kathryn
authors.initials: K
authors.lastname: Winter
authors.forename: Adam P
authors.initials: AP
authors.lastname: Dicker
authors.forename: William
authors.initials: W
authors.lastname: Small
authors.forename: Fadi W
authors.initials: FW
authors.lastname: Abdul-Karim
authors.forename: Dawn
authors.initials: D
authors.lastname: Dawson
authors.forename: Anuja
authors.initials: A
authors.lastname: Jhingran
authors.forename: Richard
authors.initials: R
authors.lastname: Valicenti
authors.forename: Joanne B
authors.initials: JB
authors.lastname: Weidhaas
authors.forename: David K
authors.initials: DK
authors.lastname: Gaffney
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D010641:Phenotype; D012189:Retrospective Studies; D012264:Ribonucleotide Reductases / Q000096:biosynthesis* / Q000235:genetics; D057170:Translational Research, Biomedical; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor; D012264:Ribonucleotide Reductases
references.citation: J Biol Chem. 2011 Apr 1;286(13):11132-40
references.pmid: 21297166
references.citation: Clin Cancer Res. 2009 Jun 15;15(12):4199-206
references.pmid: 19509178
references.citation: J Clin Oncol. 2011 May 1;29(13):1678-85
references.pmid: 21444871
references.citation: Cancer Res. 2003 Oct 15;63(20):6583-94
references.pmid: 14583450
references.citation: Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):111-7
references.pmid: 17482376
references.citation: Cancer Res. 2003 Mar 1;63(5):980-6
references.pmid: 12615712
references.citation: Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):104-9
references.pmid: 17084549
references.citation: Rev Med Virol. 2006 Mar-Apr;16(2):83-97
references.pmid: 16287204
references.citation: Clin Cancer Res. 2010 Feb 15;16(4):1298-306
references.pmid: 20145183
references.citation: J Biol Chem. 2006 Mar 24;281(12):7834-41
references.pmid: 16436374
references.citation: Radiat Res. 2011 Oct;176(4):425-33
references.pmid: 21756082
references.citation: Radiat Res. 2010 Nov;174(5):574-81
references.pmid: 20954859
references.citation: Am J Obstet Gynecol. 2010 Oct;203(4):351.e1-8
references.pmid: 20541170
references.citation: Int J Radiat Oncol Biol Phys. 1979 Mar;5(3):317-22
references.pmid: 110744
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17801-6
references.pmid: 18997010
references.citation: J Clin Oncol. 2004 Mar 1;22(5):872-80
references.pmid: 14990643
references.citation: Gynecol Oncol. 2011 Jun 1;121(3):542-5
references.pmid: 21420157
references.citation: J Clin Oncol. 1999 May;17(5):1339-48
references.pmid: 10334517
references.citation: Pharmacogenet Genomics. 2012 Apr;22(4):310-8
references.pmid: 22336956
references.citation: Annu Rev Biochem. 1988;57:349-74
references.pmid: 3052277
references.citation: J Clin Oncol. 2007 Jul 1;25(19):2804-10
references.pmid: 17502627
references.citation: Nature. 2000 Mar 2;404(6773):42-9
references.pmid: 10716435
references.citation: Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1081-7
references.pmid: 17398031
references.citation: Oncol Hematol Rev. 2012 Spring;8(1):55-60
references.pmid: 22943045
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3925-9
references.pmid: 12655059
references.citation: Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1198-204
references.pmid: 21470790
references.citation: J Biol Chem. 2000 Jun 9;275(23):17747-53
references.pmid: 10747958
references.citation: Radiat Res. 2009 Dec;172(6):666-76
references.pmid: 19929413
references.citation: Int J Gynecol Cancer. 2012 Nov;22(9):1463-9
references.pmid: 23051959
references.citation: J Biol Chem. 1985 Aug 5;260(16):9114-6
references.pmid: 3894352
references.citation: Cancer Res. 1988 Sep 15;48(18):5151-6
references.pmid: 3044582
references.citation: Gynecol Oncol. 2008 May;109(2):275-9
references.pmid: 18299147